European regulators will issue a negative opinion of Antigenics' (Nasdaq: AGEN) cancer vaccine Oncophage sending the stock price plummeting 88 cents to $1.21.
Negative Opinion Of Antigenics' Oncophage
October 21, 2009 at 14:27 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.